Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRS-1191 is an effective and selective A3 adenosine receptor antagonist (KB: 92 nM, a Ki: 31.4 nM for human A3 receptor and an IC50: 120 nM for CHO cells).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 670.00 | |
50 mg | 6-8 weeks | $ 871.00 | |
100 mg | 6-8 weeks | $ 1,490.00 |
Description | MRS-1191 is an effective and selective A3 adenosine receptor antagonist (KB: 92 nM, a Ki: 31.4 nM for human A3 receptor and an IC50: 120 nM for CHO cells). |
Targets&IC50 | A3 receptor (human):(ki)31.4 nM |
In vitro | MRS-1191 is found to be competitive in saturation binding studies using the agonist radioligand [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)adenosine-5'-N-methylbromide) at cloned human brain A3 receptor expressed in HEK-293 cells. The effects of putative A3 adenosine receptor antagonist of MRS-1191 is characterized in receptor binding and functional assays. MRS-1191 with a KB value of 92 nM, proves to be highly selective for human A3 receptor vs human A1 receptor-mediated effects on adenylate cyclase . |
Molecular Weight | 477.55 |
Formula | C31H27NO4 |
CAS No. | 185222-90-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (523.51 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MRS-1191 185222-90-6 Others MRS1191 MRS 1191 inhibitor inhibit